
Regulatory tracker: With FDA filing, J&J targets Caplyta expansion into schizophrenia relapse prevention
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Be sure to come back regularly …